HLA markers for poor prognosis in systemic sclerosis Brazilian patients

Disease Markers

Volumn 35, Issue 2, 2013, Pages 73-78

  Del Rio, Ana Paula Toledo ^a   Sachetto, Zoraida ^a   Sampaio Barros, Percival Degrava ^b   Marques Neto, João Francisco ^a   Londe, Ana Carolina Santos ^a   Bertolo, Manoel Barros ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN;

ALLELE; ARTICLE; FEMALE; FOLLOW UP; HLA TYPING; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SCLERODERMA; SYSTEMIC SCLEROSIS;

BRAZIL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; HYPERTENSION, PULMONARY; MALE; PROGNOSIS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 84882389207     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/301415     Document Type: Article

References (35)

1. H. Chifflot, B. Fautrel, C. Sordet, E. Chatelus, and J. Sibilia, "Incidence and prevalence of systemic sclerosis: a systematic literature review, " Seminars in Arthritis and Rheumatism, vol. 37, no. 4, pp. 223-235, 2008.
2. S. Bernatsky, L. Joseph, C.A. Pineau, P. Belisle, M. Hudson, and A. E. Clarke, "Scleroderma prevalence: demographic variations in a population-based sample, " Arthritis Care and Research, vol. 61, no. 3, pp. 400-404, 2009.
3. V. D. Steen and T. A. Medsger, "Changes in causes of death in systemic sclerosis, 1972-2002, " Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 940-944, 2007.
4. D. D. Gladman, T. N. Kung, F. Siannis, F. Pellett, V. T. Farewell, and P. Lee, "HLA markers for susceptibility and expression in scleroderma, " Journal of Rheumatology, vol. 32, no. 8, pp. 1481- 1487, 2005.
5. M. Kuwana, J. Kaburaki, Y. Okano, H. Inoko, and K. Tsuji, "TheHLA-DR andDQgenes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma), " Journal of Clinical Investigation, vol. 92, no. 3, pp. 1296-1301, 1993.
6. F. K. Tan, D. N. Stivers, F. C. Arnett, R. Chakraborty, R. Howard, and J. D. Reveille, "HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis), " Tissue Antigens, vol. 53, no. 1, pp. 74-80, 1999.
7. J. D. Reveille, M. Fischbach, T. McNearney et al., "Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants, " Seminars in Arthritis and Rheumatism, vol. 30, no. 5, pp. 332-346, 2001.
8. D. Frezza, V. Giambra, B. Tolusso et al., "Polymorphism of immunoglobulin enhancer element HS1, 2A: allele 2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency, " Annals of the Rheumatic Diseases, vol. 66, no. 9, pp. 1210-1215, 2007.
9. L. S. Loubìere, N. C. Lambert, M. M. Madeleine et al., "HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women, " Rheumatology, vol. 44, no. 3, pp. 318-322, 2005.
10. C. P. Simeon, V. Fonollosa, C. Tolosa et al., "Association of HLA class II genes with systemic sclerosis in Spanish patients, " Journal of Rheumatology, vol. 36, no. 12, pp. 2733-2736, 2009.
11. D. R. Karp, N. Marthandan, S. G. E. Marsh et al., "Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis, " Human Molecular Genetics, vol. 19, no. 4, pp. 707-719, 2009.
12. L. Beretta, B. Rueda, M. Marchini et al., "Analysis of class II human leucocyte antigens in Italian and Spanish systemic sclerosis, " Rheumatology, vol. 51, no. 1, pp. 52-59, 2012.
13. F. C. Arnett, P.Gourh, S. Shete et al., "Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls, " Annals of the Rheumatic Diseases, vol. 69, no. 5, pp. 822-827, 2010.
14. M. Kuwana, Y. Okano, J. Kaburaki, and H. Inoko, "HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma), " Annals of the Rheumatic Diseases, vol. 54, no. 12, pp. 983-987, 1995.
15. N. C. Lambert, O. Distler, U. Muller-Ladner, T. S. Tylee, D. E. Furst, and J. L. Nelson, "HLA-DQA1 0501 is associated with diffuse systemic sclerosis in Caucasian men, " Arthritis Rheum, vol. 43, pp. 2005-2010, 2000.
16. T. R. D. J. Radstake, O. Gorlova, B. Rueda et al., "Genome-wide association study of systemic sclerosis identifiesCD247 as a new susceptibility locus, " Nature Genetics, vol. 42, pp. 426-429, 2010.
17. X. Zhou, J. E. Lee, F. C. Arnett et al., "HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study inKoreans with replication inNorth Americans, "Arthritis and Rheumatism, vol. 60, no. 12, pp. 3807-3814, 2009.
18. J. D. Reveille, E. Durban, M. J. MacLeod-Clair et al., "Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis), " Journal of Clinical Investigation, vol. 90, no. 3, pp. 973-980, 1992.
19. F. C. Arnett, J. D. Reveille, R. Goldstein et al., "Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis, " Arthritis and Rheumatism, vol. 39, no. 7, pp. 1151-1160, 1996.
20. J. D. Reveille, D. Owerbach, R. Goldstein, R. Moreda, R. A. Isern, and F.C.Arnett, "Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma), " Journal of Clinical Investigation, vol. 89, no. 4, pp. 1208-1213, 1992.
21. C. Marguerie, C. C. Bunn, J. Copier et al., "The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl, " Medicine, vol. 71, no. 6, pp. 327-336, 1992.
22. P. A. Morel, H. J. Chang, J. W. Wilson et al., "Severe systemic sclerosiswith anti-topoisomerase I antibodies is associatedwith an HLA-DRw11 allele, " Human Immunology, vol. 40, no. 2, pp. 101-110, 1994.
23. D. Briggs, C. Stephens, R. Vaughan, K. Welsh, and C. Black, "A molecular and serologic analysis of themajor histocompatibility complex and complement component C4 in systemic sclerosis, " Arthritis and Rheumatism, vol. 36, no. 7, pp. 943-954, 1993.
24. G. C. Fanning, K. I.Welsh, C. Bunn, R. du Bois, and C. M. Black, "HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients, " British Journal of Rheumatology, vol. 37, no. 2, pp. 201-207, 1998.
25. J. D. Reveille, M. Fischbach, T. McNearney et al., "Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants, " Seminars in Arthritis and Rheumatism, vol. 30, no. 5, pp. 332-346, 2001.
26. P. Langevitz, D. Buskila, D. D. Gladman, G. A. Darlington, V. T. Farewell, and P. Lee, "HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome, " British Journal of Rheumatology, vol. 31, no. 9, pp. 609-613, 1992.
27. A. Santaniello, G. Salazar, S. Lenna et al., "HLA-B35 upregulates the production of endothelin-1 in HLA-transfected cells: a possible pathogenetic role in pulmonary hypertension, " Tissue Antigens, vol. 68, no. 3, pp. 239-244, 2006.
28. S. Lenna, D. M. Townsend, F. K. Tan et al., "HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells, " Journal of Immunology, vol. 184, no. 9, pp. 4654-4661, 2010.
29. F. C. Arnett, "HLA and autoimmunity in scleroderma (systemic sclerosis), " International Reviews of Immunology, vol. 12, no. 2- 4, pp. 107-128, 1995.
30. J. Whyte, C. Artlett, G. Harvey et al., "HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives, " Journal of Autoimmunity, vol. 7, no. 4, pp. 509-520, 1994.
31. F. C. Gilchrist, C. Bunn, P. J. Foley et al., "Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP, " Genes and Immunity, vol. 2, no. 2, pp. 76-81, 2001.
32. E.Carwile LeRoy, C. Black, R. Fleischmajer et al., "Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, " Journal of Rheumatology, vol. 15, no. 2, pp. 202-205, 1988.
33. H. Poormoghim, M. Lucas, N. Fertig, and T. A. Medsger Jr, "Systemic sclerosis sine scleroderma: demographic, clinical, and serologic factors and survival in forty-eight patients, " Arthritis Rheum, vol. 43, pp. 444-451, 2000.
34. A. Ramirez and J. Varga, "Pulmonary arterial hypertension in systematic sclerosis: clinical manifestations, pathophysiology, evaluation, and management, " Treatments in Respiratory Medicine, vol. 3, no. 6, pp. 339-352, 2004.
35. N. K.Harrison, A. R.Myers, B. Corrin et al., "Structural features of interstitial lung disease in systemic sclerosis, " American Review of Respiratory Disease, vol. 144, no. 3, pp. 706-713, 1991.